The 4 analysts offering 12-month price forecasts for Nabriva Therapeutics PLC have a median target of 2.25, with a high estimate of 7.00 and a low estimate of 1.00. The median estimate represents a +183.73% increase from the last price of 0.79.
The current consensus among 6 polled investment analysts is to Hold stock in Nabriva Therapeutics PLC. This rating has held steady since May, when it was unchanged from a Hold rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.17
Reporting Date Aug 06
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.